A Safety Study of Mirikizumab (LY3074828)

Exclusion Criteria

• •Have received treatment with biologic therapies for psoriasis (such as monoclonal antibodies, including marketed or investigational biologic therapy). Prior or current use of biologics for indications other than psoriasis may be allowed with sponsor approval
• •Within 28 days prior to baseline: have received systemic nonbiologic psoriasis therapy
• •Within 14 days prior to baseline: have received topical psoriasis treatment
• •Have presence of significant uncontrolled cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or neuropsychiatric disorders or abnormal laboratory values at screening that, in the opinion of the investigator, pose an unacceptable risk to the subject if participating in the study or of interfering with the interpretation of data
• •Have had clinically significant symptomatic herpes zoster within 3 months of screening
• •Show evidence of active or latent tuberculosis (TB)
• •Have received live vaccine(s) (included attenuated live vaccines) within 1 month of screening or intend to during the study
• •Have significant allergies to humanized monoclonal antibodies or any components of the mirikizumab product formulation or have a history of significant atopy
• •Have had lymphoma, leukemia, or any malignancy within the past 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years and cervical carcinoma in situ, with no evidence of recurrence within 5 years prior to baseline